Raise Capital
Products
Resources
December 7, 2023
Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.
Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?
Start Date | End Date | Type | Platform | Amount Raised | # Investors |
---|---|---|---|---|---|
3/13/19 | 3/31/20 | A+ | SeedInvest | $14,588,668 | 6,000 |
11/16/20 | 1/16/21 | A+ | StartEngine | $2,965,501 | 8,000 |
1/17/21 | 2/18/22 | A+ | StartEngine | $23,647,853 | 14,082 |
7/15/22 | 3/16/23 | CF | DealMaker | $4,673,000 | 2,249 |
3/1/23 | 4/8/23 | A+ | Republic | $232,275 | 120 |
3/1/23 | 5/23/23 | A+ | DealMaker | $15,958,364 | 5,198 |
5/18/23 | - | Nasdaq listing | |||
7/24 | 10/24 | Unit Offering | DealMaker | $12,990,103 | 2,745 |
Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.
Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.
DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.
Targeted campaigns in premium publications like Morning Brew captured qualified investors
Engaging events that generated over $4.3 million in investments
Strategic approaches that fostered a loyal shareholder base
Innovative approaches that amplified investment momentum
Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:
In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.
For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.
Public perception says you can't raise privately post-IPO. Monogram proved that wrong.
Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.
The strategic private offering conducted through DealMaker helped drive awareness and interest in Monogram's public shares, contributing to positive market performance during the raise period.
This was retail capital at its best: strategic, repeatable, and aligned.
This wasn't a one-time raise. It was a multi-year capital strategy.
Retail capital helped Monogram:
This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.
Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.
Explore Raising Capital with DealMaker